Pluripotency strongly associates with global DNA hypomethylation in the inner cell mass (ICM) of blastocysts, their embryonic stem (ES) cell derivatives \[[@r1], [@r2]\], and induced pluripotent stem (iPS) cells \[[@r3]−[@r5]\]. Several studies have shown that global DNA hypomethylation is the most important contributor to the pluripotency of these cell types. This is largely through promoting transcription of genes important for maintaining self-renewal and repressing differentiation \[[@r6],[@r7],[@r8]\]. During the induced-reprogramming of somatic cells to generate iPS cells, demethylation is the key to establish the global DNA hypomethylation that is associated with pluripotency. This is similar to the process that naturally occurs during preimplantation development \[[@r9],[@r10],[@r11]\]. Prior work has also indicated that DNA demethylation is required for the process of mesenchymal-epithelial transition (MET), during which some of the ﬁrst detectable changes in early reprogramming stage occur \[[@r12]\]. It is hypothesized that if DNA methylation is not fully removed during iPS cell generation, a signiﬁcant proportion of cells remain trapped in a partially reprogrammed state \[[@r11]\].

DNA methyltransferases (DNMTs) have previously been considered a major barrier to reprogramming \[[@r10]\]. Treatment with 5-aza-2'-deoxycytidine (AZA, a non-specific inhibitor of DNMTs) facilitates the generation of pluripotent stem cells from somatic cells under different reprogramming systems \[[@r10], [@r11], [@r13]\]. Furthermore, silencing *Dnmt1* and *Dnmt3b* promotes somatic cell reprogramming by demethylating pluripotency-associated gene promoters \[[@r11], [@r14]\]. However, at later stage of reprogramming, upregulation of *Dnmt*s expression is essential to the developmental potential of fully pluripotent iPS cells \[[@r15]\]. This is supported by data showing that ES cells deficient in *Dnmt1* and/or *Dnmt3a/3b* have impaired pluripotency and differentiation potential \[[@r16], [@r17]\]. Together, these studies highlight the fact that DNMT expression is highly dynamic and must be precisely controlled during somatic cell reprogramming.

MicroRNAs (miRNAs) are critical regulators of gene expression that function by either targeting speciﬁc mRNAs for degradation or through suppressing translation. Remarkably, they have been virtually implicated in reprogramming, pluripotency and differentiation, by orchestrating the expression of key regulators of pluripotency and differentiation, including pluripotency factors, *Dnmts*, and apoptotic genes \[[@r18], [@r19]\]. In addition, the importance of miRNAs to the establishment and maintenance of pluripotency is further demonstrated by studies indicating that transfection of speciﬁc miRNA mimics, or administration of miRNA inhibitors, can promote somatic cell reprogramming \[[@r20],[@r21],[@r22],[@r23],[@r24]\].

In many cases, specific mRNA can be targeted by more than one miRNA via both mRNA degradation by targeting sites in the 3' untranslated regions (UTRs) and translation inhibition by targeting sites in the coding sequences (CDSs) \[[@r25], [@r26]\]. This led us to postulate that miRNA functional redundancy may be involved in the regulation of *Dnmt*s during somatic cell reprogramming. To investigate this hypothesis, our study used QRT-PCR to screen miRNA expression patterns from our previously published miRNA dataset \[[@r27]\]. This identified miR-6539 as a miRNA with a unique expression dynamic during somatic cell reprogramming. Specifically, miR-6539 expression was significantly higher during the early phase of reprogramming and then consistently lowered until the formation of iPS cells. These dynamics correlated inversely with the protein levels of DNMT3B during reprograming, suggesting that *Dnmt3b* was a potential target of miR-6539. These data led us to speculate that miR-6539 is significantly involved in somatic cell reprogramming. To investigate this hypothesis, we utilized a secondary inducible system that used doxycycline (Dox)-controlled Tet-on inducible OSKM (*Oct4*, *Sox2*, *Klf4*, and *c-Myc*). This system has previously been shown to be effective at evaluating reprogramming efficiency due to consistent proviral integration \[[@r28],[@r29],[@r30]\]. Using the system, we confirmed that miR-6539 was a novel mediator that repressed *Dnmt3b* expression during somatic cell reprograming. More importantly, our results indicated that miR-6539 facilitates *Dnmt3b* repression by inhibiting translation via a target site in the CDS. To the best of our knowledge, our study is the first to report miRNA-mediated translation inhibition by targeting the CDS during induced somatic cell reprogramming. These data contribute to the understanding of mechanisms that underlie miRNA-involved epigenetic remodeling during reprogramming.

Materials and Methods {#s1}
=====================

Animals
-------

All mice were housed in an animal facility at normal temperatures (20 ± 2°C), under a controlled light cycle (12 h light: 12 h dark), and with free access to water and food. All procedures were performed in accordance with protocols described in the China Agricultural University Guide for the Care and Use of Laboratory Animals.

Cell culture
------------

Our study used a secondary inducible system, in which four doxycycline (Dox)-inducible transcription factors, *Oct4*, *Sox2*, *Klf4*, and *c-Myc*, were transduced into mouse embryonic fibroblasts (MEFs) isolated from ROSA26-M2rtTA transgenic mice. Secondary-inducible MEFs were produced from all-iPS cell mice through tetraploid complementation \[[@r28], [@r30]\].

MEFs and secondary MEFs were cultured in a fibroblast medium containing DMEM (Gibco, Life Technologies, Grand Island, NY, USA), supplemented with 10% FBS (Gibco, Life Technologies), 1 mM L-glutamine, 1% nonessential amino acids, and penicillin/streptomycin (Chemicon, Temecula, CA, USA). iPS cells were cultured on mitomycin C (MMC)-treated MEFs in ES medium, which contained DMEM supplemented with 15% FBS, 1 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 1% nonessential amino acids, and 1000 U/ml leukemia inhibitory factor (all from Chemicon, Temecula).

Vectors
-------

DNA template encoding the precursor sequence of miR-6539 was amplified by PCR from genomic DNA isolated from a mouse liver. This was cloned into the *Bam*HI and *Eco*RI restriction sites of a PCDH5 plasmid to construct the overexpression vector for miR-6539. The wild-type (WT) *Dnmt3b* CDS fragment (including the predicted target site) was amplified from mouse cDNA, while the mutant (Mut) *Dnmt3b* CDS fragment was synthesized by Beijing Zixi Bio Tech, Beijing, China. The plasmids '*Dnmt3b* WT' and '*Dnmt3b* Mut' were generated by inserting the wild-type *Dnmt3b* CDS fragment and mutant *Dnmt3b* CDS fragment into the *Not*I and *Xho*I restriction sites of psiCHECK-2 plasmid, respectively. All plasmids created during this study were verified by sequencing. The primers used for vector construction are included in [Table 1](#tbl_001){ref-type="table"}Table 1.Primers usedPrimerSequence (5′--3′)ApplicationPre-miR-6539-FCGGGAATTCGAAGAATGTCCTTCACCTATTGCloning for miR-6539 overexpression vectorPre-miR-6539-RCCTGGATCCCCTATAGGGAGCTGTGAAAATCCloning for miR-6539 overexpression vectorDnmt3b WT-FGCACTCGAGGTTGTACCCAGCAATTCCTGCloning for *Dnmt3b* WT vectorDnmt3b WT-RTTAGCGGCCGCGATTGACGTTAGAGAGATCATTGCloning for *Dnmt3b* WT vectorGapdh-FTGCCCCCATGTTTGTGATGQRT-PCR for *Gapdh*Gapdh-RTGTGGTCATGAGCCCTTCCQRT-PCR for *Gapdh*Oct4-FTCTTTCCACCAGGCCCCCGGCTCQRT-PCR for *Oct4*Oct4-RTGCGGGCGGACATGGGGAGATCCQRT-PCR for *Oct4*Sox2-FTAGAGCTAGACTCCGGGCGATGAQRT-PCR for *Sox2*Sox2-RTTGCCTTAAACAAGACCACGAAAQRT-PCR for *Sox2*Nanog-FAGGGTCTGCTACTGAGATGCTCTGQRT-PCR for *Nanog*Nanog-RCAACCACTGGTTTTTCTGCCACCGQRT-PCR for *Nanog*Dnmt3b-FTTATCGTTAATGGGAACTTCAGTGQRT-PCR for *Dnmt3b*Dnmt3b-RCATGTCCTGCGTGTAATTCAGQRT-PCR for *Dnmt3b*Me-Oct4-out-FGAGGATTGGAGGTGTAATGGTTGTTMethylation analysis of *Oct4*Me-Oct4-out-RCTACTAACCCATCACCCCCACCTAMethylation analysis of *Oct4*Me-Oct4-in-FTGGGTTGAAATATTGGGTTTATTTMethylation analysis of *Oct4*Me-Oct4-in-RCTAAAACCAAATATCCAACCATAMethylation analysis of *Oct4*Me-Nanog-out-FAAGTATGGATTAATTTATTAAGGTAGTTMethylation analysis of *Nanog*Me-Nanog-out-RAAAAAACCCACACTCATATCAATATAMethylation analysis of *Nanog*Me-Nanog-in-FAAGTATGGATTAATTTATTAAGGTAGTTMethylation analysis of *Nanog*Me-Nanog-in-RCAACCAAATAACCTATCTAAAAAMethylation analysis of *Nanog*.

Generation of iPS cells and miR-6539-derived iPS cells
------------------------------------------------------

Secondary MEFs were seeded at 2 × 10^4^ cells per well on a gelatin-coated 12-well plate. After ES cell-like colonies had developed (typically day 12 after addition of 1 µg/ml Dox), the media were replaced with ES cell medium for 2--3 days. Colonies were then mechanically isolated and digested to be cultured as ES cells on MMC--treated MEFs.

For miR-6539-derived iPS cells, secondary MEFs were transfected the day after seeding with 200 nM miR-6539 mimic by Lipofectamine 2000 (Invitrogen, Life Technologies, Carlsbad, CA, USA), according to the manufacturer's recommendations. Twenty-four hours after transfection with the miR-6539 mimic, culture medium was replaced with ES medium and supplemented with 1 µg/ml Dox. Media were changed daily. After ES cell-like colonies had developed (again, approximately day 12 after 1 µg/ml Dox addition), the medium was replaced with ES medium without Dox and cells were incubated for a further 2--3 days. Finally, colonies were mechanically isolated and digested for culturing on MMC-treated MEFs.

Alkaline phosphatase (AP) staining
----------------------------------

AP staining was performed using an Alkaline Phosphatase Detection Kit (Sigma-Aldrich, St. Louis, MO, USA), following the instructions of the manufacturer. Cells were stained at day 8 after the addition of 1 µg/ml Dox when iPS colonies had developed.

Reverse Transcription PCR (RT-PCR)
----------------------------------

Total RNA was extracted from cell pellets using TRIzol reagent (Invitrogen, Life Technologies). Each RNA sample was treated with DNase I (Thermo Scientific™, \*\*manufacturer's name, located city, country\*\*) to remove any potentially contaminating genomic DNA and then used as a template for reverse transcription with an iScriptTM cDNA synthesis kit (Bio-rad, Hercules, CA, USA), according to the manufacturer's recommendations. The primers for ES cell marker genes are listed in [Table 1](#tbl_001){ref-type="table"}.

Quantitative RT-PCR (QRT-PCR) to assess expression of miRNAs and marker genes
-----------------------------------------------------------------------------

For miRNA quantification, the Bulge-LoopTM miRNA qPCR Primer Set (RiboBio, Guangzhou, China) was used to detect miRNA expression with a SYBR Green-based PCR Master Mix (Bio-rad) and a Bio-rad CFX96 Real-Time PCR System. For marker gene quantification, a 1/10 dilution of cDNA was used as a template with a SYBR Green-based PCR Master Mix (Bio-rad) on a Bio-rad CFX96 Real-Time PCR System. The relative expression levels of miRNAs and mRNAs were calculated using the 2^--ΔΔCt^ method and either U6 or glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) as internal controls, respectively, using a previously reported protocol \[[@r23]\].

Bisulfite sequencing
--------------------

Genomic DNA was extracted using a genomic DNA extraction kit (TIANGEN, Beijing, China) and the standard protocol. The extracted DNA was then treated with a Methylamp DNA Modification kit (Epigentek, New York, NY, USA) and used as a template to amplify sequences in the promoter regions of *Oct4* and *Nanog* using a two-round, nested PCR. Subsequent PCR products were cloned into vectors using a pEASY-T5 Zero cloning kit (TransGen Biotech, Beijing, China). For validation, five randomly selected clones were sequenced.

Western blot
------------

Forty-eight hours after transfection with the miR-6539 overexpression vector and corresponding control vector, HEK293T cells were washed twice using PBS and lysed using RIPA buffer (CWBio, Beijing, China). Equivalent amounts of protein from each sample were separated on SDS-PAGE gels and then transferred to polyvinylidene fluoride (PVDF) membranes. These were then incubated overnight at 4°C in blocking solution with the primary antibodies anti-DNMT3B (1:1000; Abcam, Cambridge, UK; mouse monoclonal antibody to DNMT3B, Cat\#: ab13604) or anti-β-actin (1:2000; Abcam, mouse monoclonal antibody to β-actin, Cat\#: ab8226) (β-actin was selected as a loading control). ECL peroxidase-labeled anti-mouse antibody (1:5000, ZsBio, Beijing, China) was used as the secondary antibody. Finally, data were analyzed using ImageJ software (<https://imagej.nih.gov/ij/>).

Dual-luciferase reporter assay
------------------------------

HEK293T cells in 24-well plates were transfected with 400 ng miR-6539 overexpression vector and 400 ng psiCHECK-2 vector (Promega, Madison, WI, USA) using Lipofectamine 2000 (Invitrogen, Life Technologies). Forty-eight hours post-transfection, cell lysates were collected and the Firefly and Renilla luciferase signals measured using a dual-luciferase reporter assay system (Promega), according to the instructions of the manufacturer. Firefly reporter activity was used to normalize the Renilla luciferase signal.

Statistical analyses
--------------------

All data are presented as the mean ± SD from three independent experiments. Differences between control and experimental groups were evaluated using two-tailed Student's *t*-tests, where \*, \*\*, and \*\*\* indicate P \< 0.05, P \< 0.01, and P \< 0.001, respectively.

Results and Discussion {#s2}
======================

The expression of miR-6539 inversely correlated with Dnmt3b expression during somatic cell reprogramming
--------------------------------------------------------------------------------------------------------

To explore the potential role of miRNAs in somatic cell reprogramming, we filtered miRNAs from our previous miRNA expression dataset that were highly enriched in MEFs or iPS cells ([Fig. 1A and B](#fig_001){ref-type="fig"}Fig. 1.Generation of iPS cells using a secondary inducible system and the expression dynamics of miR-6539 and *Dnmt3b.* (A) A schematic diagram illustrating the process for generating iPS cells using a secondary inducible system. (B) Expression profiles of candidate miRNAs that were enriched in MEFs or iPS cells. (C) Expression dynamics of miR-6539 during somatic cell reprogramming, assessed using QRT-PCR. (D) Expression dynamics of *Dnmt3b* mRNA during somatic cell reprogramming, assessed using QRT-PCR. (E) Expression dynamics of DNMT3B protein during somatic cell reprogramming, assessed by western blot. The right panel shows the relative protein level of DNMT3B, based on the quantification of signal intensity from three independent experiments. (F) The correlation between miR-6539 expression and *Dnmt3b* mRNA or protein levels. *\** (P \< 0.05) and \*\* (P \< 0.01) indicate expression levels that are significantly different from day 0.) \[[@r27]\]. For each potentially associating miRNA, the expression dynamics during reprogramming were evaluated using QRT-PCR. This revealed that most potential miRNAs were highly dynamic during reprogramming in a secondary inducible system. However, among this group of miRNAs, we noted that miR-6539 had a unique expression dynamic. During the early stage of reprogramming, miR-6539 was markedly higher, with a peak on day 4. After this peak, miR-6539 expression consistently decreased until the formation of iPS colonies ([Fig. 1C](#fig_001){ref-type="fig"}). This dynamic was the inverse of DNMT3B protein levels during reprogramming, but not *Dnmt3b* mRNA levels ([Figs. 1](#fig_001){ref-type="fig"}D--F). Previous studies have shown that there are two phases of DNMT expression during somatic cell reprogramming. During the early phase, DNMT levels are lower to facilitate global DNA demethylation as high DNMT abundance blocks the demethylation process \[[@r11]\]. Furthermore, treatment with DNMT inhibitors promotes iPS cell induction \[[@r10], [@r11], [@r13]\]. However, during the late phase, levels of DNMT3A and DNMT3B protein are elevated \[[@r23]\]. *Dnmt3a*- and *Dnmt3b*-deficient iPS cells also show restricted developmental potential \[[@r15]\], suggesting that DNMTs are required for full pluripotency.

Next, we used the miRNA target prediction software packages TargetScan, Miranda, and miRBase to identify potential binding sites for miR-6539. This analysis highlighted *Dnmt3b* as a likely target of miR-6539 during reprogramming via a target site in the CDS located within the C-terminal domain (exon 16 of transcript variant 1). Further analysis showed that this target site is common to all nine transcript variants of *Dnmt3b*. These data, together with the inverse correlation we identified between miR-6539 and DNMT3B protein levels, led us to hypothesize that miR-6539 is significantly involved in epigenetic remodeling during somatic cell reprogramming, likely by affecting the expression dynamics of DNMT3B.

miR-6539 facilitates DNA demethylation during the earlier phase of reprogramming and promotes iPS cell formation
----------------------------------------------------------------------------------------------------------------

To determine if miR-6539 facilitates DNA demethylation during the earlier phase of reprogramming, we detected the methylation status of *Oct4* and *Nanog* promoter regions after overexpressing miR-6539. Demethylation of these genes has previously been shown to be critical to pluripotency and important to reprogramming \[[@r31]\]. As shown in [Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Effect of miR-6539 overexpression or inhibition on iPS cell formation. (A) Effects of enforced upregulation of miR-6539 on DNA methylation patterns at the promoter regions of *Oct4* and *Nanog* during the early phase of reprogramming. Open and closed circles indicate unmethylated and methylated CpG dinucleotides, respectively. Tables show the percentages of methylated CpGs in the promoter regions of *Oct4* and *Nanog*. (B) A schematic outlining the strategy for upregulating or downregulating miR-6539 during the early stage of reprogramming. (C) Quantification and (D) representative images of AP+ colonies after transfection with miR-6539 mimic or inhibitor. *\** P \< 0.05, \*\* P \< 0.01., enforced upregulation of miR-6539 induced rapid demethylation of the *Oct4* and *Nanog* promoter regions during the early phase of reprogramming, compared to untransfected and mimic control groups.

Next, to further identify the role of miR-6539 in overcoming the epigenetic barrier to somatic cell reprogramming, we determined whether enforced upregulation of miR-6539 facilitated reprogramming efficiency ([Fig. 2B](#fig_002){ref-type="fig"}). This showed that enforced upregulation of miR-6539 during the early phase of reprogramming significantly increased the number of alkaline phosphatase positive (AP^+^) iPS colonies, compared to mimic control ([Fig. 2C](#fig_002){ref-type="fig"}). These iPS colonies were also found to passage normally with a well-characterized morphology ([Fig. 2D](#fig_002){ref-type="fig"}). In contrast, the efficiency of iPS cell generation was greatly decreased when miR-6539 inhibitor was introduced during somatic cell reprogramming ([Fig. 2C](#fig_002){ref-type="fig"}). These results show that miR-6539 is involved in the induction of iPS cells.

Our study supports prior work by Guo *et al*. \[[@r23]\], and confirms a well-known relationship between miRNAs and target genes, by showing that a single miRNA can target many genes (miR-29b targets both *Dnmt3a* and *Dnmt3b*) and conversely, one gene may also be targeted by many miRNAs (for example, *Dnmt3b* is targeted by both miR-29b and miR-6539). This 'multiple-to-multiple' relationship between miRNAs and their target genes, previously shown to be involved in carcinogenesis \[[@r32],[@r33],[@r34],[@r35]\], also has an essential role during somatic cell reprogramming.

Pluripotency characterization of miR-6539-derived iPS cells
-----------------------------------------------------------

To examine the pluripotency of iPS cells after the introduction of miR-6539 (miR-6539-derived iPS cells), we first assessed the expression of several endogenous pluripotency markers (*Oct4*, *Sox2*, and *Nanog*), from three different miR-6539-derived iPS cell lines, using RT-PCR ([Fig. 3A](#fig_003){ref-type="fig"}Fig. 3.Pluripotency analyses of miR-6539-derived iPS cells. (A) Expression of pluripotent transcription factors (*Oct4*, *Nanog*, and *Sox2*) in miR-6539-derived iPS cell lines, assessed using RT-PCR. (B) QRT-PCR analysis of *Oct4, Nanog*, and *Sox2* mRNA levels in miR-6539-derived iPS cell lines, R1 ES cells, and control iPS cells and MEFs. (C) Bisulfite sequencing of the promoter regions of *Oct4* and *Nanog* in miR-6539-derived iPS cells, R1 ES cells, control iPS cells, and MEFs. The table shows the percentages of methylated CpGs in the promoter regions of *Oct4* and *Nanog* in different cell types.). Results from QRT-PCR further indicated that expression of these pluripotency markers in miR-6539-derived iPS cells was comparable to that in control iPS and R1 ES cells ([Fig. 3B](#fig_003){ref-type="fig"}). Supporting previous studies, fully activated endogenous pluripotency genes, *Oct4* and *Nanog*, had hypomethylation in their promoter regions ([Fig. 3C](#fig_003){ref-type="fig"}). In summary, these data show that the pluripotency-associated characteristics of miR-6539-derived iPS cells are comparable to those of control iPS and ES cells.

miR-6539 represses the translation process of Dnmt3b via the target site in the CDS
-----------------------------------------------------------------------------------

To understand the mechanisms that underlie the effect that miR-6539 expression had on somatic cell reprogramming, we investigated the potential miR-6539 target site in *Dnmt3b*. This site in the CDS was predicted by three separate target prediction programs (TargetScan, Miranda, and miRBase). Luciferase reporters were constructed that had either the wild-type (WT) or a mutant (Mut) target *Dnmt3b* sequence ([Fig. 4A](#fig_004){ref-type="fig"}Fig. 4.miR-6539 represses the translation of *Dnmt3b* via a target site located in the CDS. (A) A diagram showing the complementary interaction between miR-6539 and the target site in the CDS of *Dnmt3b*. (B) Relative luciferase activity after transfection with luciferase reporter vectors containing WT or Mut *Dnmt3b* CDS. (C) QRT-PCR analysis of the effect that miR-6539 overexpression had on *Dnmt3b* mRNA expression level. (D) Western blot analysis of the effect that miR-6539 overexpression had on DNMT3B protein level. β-actin was used as loading control. *\** P \< 0.05.). Compared to the empty control vector, overexpression of miR-6539 significantly suppressed luciferase activity of the construct containing the wild-type target sequence of *Dnmt3b*. Moreover, this inhibitory effect was significantly attenuated when the luciferase construct containing the mutant target sequence of *Dnmt3b* was used ([Fig. 4B](#fig_004){ref-type="fig"}). These results indicate that miR-6539 specifically suppressed *Dnmt3b* via targeting its CDS.

As CDS-targeting miRNAs typically lead to translation inhibition \[[@r36]\], we assessed the endogenous expression of *Dnmt3b* at both the mRNA and protein levels after overexpressing miR-6539. As expected, *Dnmt3b* mRNA levels were not significantly changed ([Fig. 4C](#fig_004){ref-type="fig"}) but DNMT3B protein abundance was significantly decreased ([Fig. 4D](#fig_004){ref-type="fig"}). Taken together, our results indicated that miR-6539-mediated suppression of *Dnmt3b* was via translation inhibition, rather than mRNA degradation, through a complementary interaction with the target site in the CDS.

There have been several studies showing that miRNAs are involved in somatic cell reprogramming \[[@r37],[@r38],[@r39],[@r40]\]. However, miRNA-mediated translation inhibition through targeting the CDS has not previously been reported. There are also increasingly more miRNA target sites being discovered in the CDSs of mammalian transcripts \[[@r41], [@r42]\]; however, our study is the first to demonstrate that miRNA-induced translation inhibition is involved in epigenetic remodeling during induced somatic cell reprogramming.

In summary, we have shown that miR-6539 is a novel mediator of somatic cell reprogramming that represses the translation of *Dnmt3b*. Upregulating miR-6539 during the early stage of somatic cell reprogramming may therefore be essential for reprogramming through demethylation of pluripotent genes. In addition, as miR-29b can target both *Dnmt3a* and *Dnmt3b* via sites in their 3' UTRs, it can be concluded that the 'multiple-to-multiple' relationship between miRNAs and target genes is also critical for induced somatic cell reprogramming. Importantly, this is the first report to show that miRNA-induced translation inhibition is involved in epigenetic remodeling during somatic cell reprogramming. This study provides a new insight into the mechanisms of miRNA-mediated epigenetic remodeling during somatic cell reprogramming.
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